Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Enzyme-Activating Antibodies Revealed As Marker for Severe Rheumatoid Arthritis

Published: Thursday, May 30, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
Finding could lead to earlier diagnosis and new, more aggressive treatment for worst cases.

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe cases of the disease, the immune system makes a unique subset of antibodies that have a disease-promoting role.

 Reporting in the journal Science Translational Medicine online May 22, the Johns Hopkins team describes how it found the novel antibodies to peptidylarginine deiminase 4, or PAD4, in blood samples from people with aggressive inflammation and connective tissue damage.

 Researchers say the presence of so-called PAD3/PAD4 cross-reactive autoantibodies could serve as the basis for the first antibody-specific diagnostic test to distinguish those with severe rheumatoid arthritis from those with less aggressive forms of the disease.

 “Identifying early on a subset of patients with severe rheumatoid arthritis could benefit their health, as these patients could start aggressive drug therapy immediately and find the most effective treatment option,” says senior study investigator Antony Rosen, M.D. Rosen, director of rheumatology and the Mary Betty Stevens Professor at the Johns Hopkins University School of Medicine, says that a third, or 1 million of the more than 3 million Americans – mostly women – estimated to have rheumatoid arthritis have an aggressive form of the disease.

 In the study, the antibodies were present – in 18 percent of 44 fluid samples from one research collection and in 12 percent of another collection of 194 – but only in people with severe cases of rheumatoid arthritis. Past research shows that those with the most aggressive disease are less likely to respond to anti-inflammatory treatments with steroids and other drugs.

 An examination of patients’ medical records revealed that 80 percent of patients with the antibody saw their disease worsen over the previous year, while only 53 percent without the antibody showed disease progression. In comparing average scores of disease-damaged joints, researchers found that those with the antibody had an average deterioration in joints and bones by a score of 49. Those without the antibody had an average degradation in their score of 7.5, indicating much milder disease.

 In a related finding, the Johns Hopkins team also uncovered how the PAD3/PAD4 cross-reactive auto-antibodies might contribute to more severe, erosive disease in rheumatoid arthritis. The team performed a series of experiments to gauge the antibodies’ effects on PAD4 in response to varying cell levels of calcium, on which PAD enzymes depend.

Lab experiments showed that the antibodies greatly increase PAD4 enzyme function at the low levels of calcium normally present in human cells. Results showed that PAD4 activity was 500 times greater in the presence of antibodies than when they were absent. Tests of the antibody and enzymes’ chemical structures later showed that the antibodies bind to PAD4 in the same region as calcium, suggesting to researchers that the antibodies might be substituting for calcium in activating the enzyme.

 According to Rosen, the series of experiments, which took two years to complete, represents the first evidence of an antibody having a direct role in generating the targets of the immune response, or auto-antigens, in rheumatoid arthritis.

 “Our results suggest that drugs inhibiting the PAD4 enzyme may have real benefit in patients with severe rheumatoid arthritis and represent an important field of study for investigating new and alternative treatments,” says lead study investigator and biologist Erika Darrah, Ph.D.

Darrah says the team next plans long-term monitoring of arthritis sufferers to find out when the antibody first appears in the blood, and when intervention may have maximum impact in preventing or stalling disease progression. The team also plans further experiments to see if the antibody is taking control of the chemical pathways normally used by other cell proteins to control PAD4 sensitivity to calcium.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Paternal Sperm May Hold Clues to Autism
Tags on DNA from fathers’ sperm linked to children’s autism symptoms.
Friday, April 17, 2015
New Autism-Causing Genetic Variant Identified
Novel approach expected to be useful for other diseases too.
Saturday, March 28, 2015
Bad Luck of Random Mutations Plays Predominant Role in Cancer, Study Shows
Statistical modeling links cancer risk with number of stem cell divisions.
Tuesday, January 06, 2015
Enzyme's Alter Ego Helps Activate the Immune System
Findings could shed light on related Alzheimer's protein.
Tuesday, January 06, 2015
Researchers Tease Out Glitches in Immune System's Self-Recognition
A new study revises understanding of how the process works and sheds light on autoimmune disease.
Saturday, November 22, 2014
Cancer Leaves a Common Fingerprint on DNA
Chemical alterations to genes appear key to tumor development.
Tuesday, August 26, 2014
Researchers Use Human Stem Cells to Create Light-Sensitive Retina in a Dish
Johns Hopkins researchers have created a 3-D complement of human retinal tissue in the laboratory.
Saturday, June 14, 2014
Signals Found That Recruit Host Animals’ Cells, Enabling Breast Cancer Metastasis
Mouse studies suggest that blocking aid from white blood cells and stem cells could keep tumors contained.
Thursday, May 22, 2014
Common Genetic Pathway Could Be Conduit to Pediatric Tumor Treatment
Investigators have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas.
Monday, November 11, 2013
A Simple Blood Test May Catch Early Pancreatic Cancer
Currently, disease usually found too late to save lives.
Wednesday, October 30, 2013
New Testing Strategy Detects Population-Wide Vitamin and Mineral Deficiencies
Could speed mass intervention in developing countries.
Wednesday, October 30, 2013
Stem Cells may do Best with a Little Help from their Friends
“Helper cells” improve survival rate of transplanted stem cells, mouse study finds.
Wednesday, September 11, 2013
Molecular Marker Predicts Patients Most Likely to Benefit Longest From Two Popular Cancer Drugs
Preliminary study needs further confirmation.
Wednesday, September 11, 2013
Discovery Increases Diagnostic Certainty and Opportunity for Individualized Drug Therapy
Of the over 1,900 errors already reported in the gene responsible for CF, it is unclear how many of them actually contribute to the inherited disease.
Thursday, August 29, 2013
Crucial Brain-Signaling Molecule Requires Coordinated Motion to Turn On
Study could help yield new drugs for brain disorders.
Monday, August 12, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!